

Product datasheet for TL310469V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

PGM1 Human shRNA Lentiviral Particle (Locus ID 5236)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: PGM1 Human shRNA Lentiviral Particle (Locus ID 5236)

Locus ID: 5236

Synonyms: CDG1T; GSD14

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: PGM1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001172818, NM 001172819, NM 002633, NM 002633.1, NM 002633.2, NM 001172819.1,

NM 001172818.1, BC019920, BC019920.1, BC001756, BC067763, BC090856, NM 002633.3

UniProt ID: P36871

Summary: The protein encoded by this gene is an isozyme of phosphoglucomutase (PGM) and belongs

to the phosphohexose mutase family. There are several PGM isozymes, which are encoded by different genes and catalyze the transfer of phosphate between the 1 and 6 positions of glucose. In most cell types, this PGM isozyme is predominant, representing about 90% of total

PGM activity. In red cells, PGM2 is a major isozyme. This gene is highly polymorphic.

Mutations in this gene cause glycogen storage disease type 14. Alternativley spliced transcript variants encoding different isoforms have been identified in this gene.[provided by RefSeq,

Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).